Release Date: 23/06/16 16:16 Summary: Letter to Shareholders-DSH.AX Price Sensitive: No Download Document 160.3KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%